| Title |
Review: role of current pancreatic ductal adenocarcinoma biomakers: ca19-9 and cea. limitations and future perspectives / |
| Translation of Title |
Review: Role of Current Pancreatic Ductal Adenocarcinoma Biomakers: CA19-9 and CEA. Limitations and future perspectives. |
| Authors |
Hayes, Fidel |
| Full Text |
|
| Pages |
21 |
| Keywords [eng] |
PDAC, CA 19-9, CEA, Biomarkers, Limitations, Future perspectives. |
| Abstract [eng] |
Pancreatic ductal adenocarcinoma (PDAC) accounts for over 90% of pancreatic cancers, hence the reason the terms have been used interchangeably over the years. It is one of the most aggressive and brutal cancers known, due to its initial silent asymptomatic presentation which later grows into a mass that produces symptoms. As pancreatic cancer incidence grows in developed countries, it is estimated to overthrow colorectal cancer by the year 2030. With a five-year survival rate of less than 12%, early diagnosis and screening have been the focus point of studies concerning the disease with biomarkers Carbohydrate Antigen 19-9 (CA 19-9) and Carcinoembryonic Antigen (CEA) leading the way. These biomarkers have shown promise and are routinely used to detect pancreatic cancer, but there are major limitations to their use. The specificity and sensitivity of both Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen are still suboptimal in asymptomatic individuals. Scientists have tackled this problem by adding and combining the findings of several promising biomarkers instead of reviewing them individually. The goal of this review was to update our understanding of CA 19-9 and CEA regarding pancreatic cancer and to find out any future implementations of the biomarkers. Another goal was to highlight where the biomarkers might fall short and emphasize what future studies should pay attention to. |
| Dissertation Institution |
Vilniaus universitetas. |
| Type |
Master thesis |
| Language |
English |
| Publication date |
2024 |
